SlideShare a Scribd company logo
1 of 10
RESTRICTED DRUGS
Risk Evaluation and Mitigation Strategies--REMS
With each drug/biologic safety issue posing a serious risk,
the question for FDA will be: to REM or not to REM?
REMS---Food and Drug Administration
Amendments Act of 2007
in 2006 the FDA listed 156 REMS for prescription
medicines (128) and biologics (28)
intended to ensure the benefits of the medication outweigh
its risk
why REMS??--Public outcry over revelations of
unforeseen risks from trusted medicines(rofecoxib,
valdecoxib, and salmeterol
RESTRICTED DRUGS
 FDA can require a manufacturer to implement a REMS
 Components of REMS
 1--Medication Guides--required for drugs and
biologics when the FDA determines that: (a) certain
information is necessary to prevent serious adverse
effects, (b) patient decision-making should be
informed by information about a known serious side
effect of a product, or (c) patient adherence to
directions for the use of a product is essential to its
effectiveness.
RESTRICTED DRUGS
 2--Communication Plans--
 Letters to healthcare providers;
 Disseminating information about the REMS to
encourage implementation; and
 Disseminating information through professional
societies about any serious risks of the drug and any
protocol to assure safe use.
RESTRICTED DRUGS
 3--Elements to Assure Safe Use(ETASU)
 may include one or more of the following
 Special training, certifications, or demonstration of
experience for prescribers of the drug/biologic
 Certification of pharmacies, practitioners, or healthcare
settings that dispense the drug/biologic
 Limitations as to the healthcare settings where the
drug/biologic may be dispensed
 Evidence of special safe-use conditions--patients receive the
drug/biologic only after specified authorization,proof of
counseling, periodic blood tests
 monitor the number of prescriptions dispensed, adverse
events,
Examples of Drugs with REMS
 alosetron (Lotronex)
 clozapine (Clozaril, Fazaclo)
 isotretinoin (Accutane, Amnesteem,
Claravis, Sotret)
 thalidomide (Thalomid)
 dofetilide (Tikosyn)
Alosetron
 Treats a type of irritable bowel syndrome (IBS)
 Serious adverse reactions of gastrointestinal
tract
 some necessitate a blood transfusion or surgery
 some even lead to death
 Restricted by Prescription Program for
Lotronex (PPL)
 requires physician enrollment & submission of Patient-
Physician Agreement Form
 Prescriptions must be written by physician & must
include PPL sticker on face of prescription
Clozapine
 Treats patients with schizophrenia
 Can cause serious drop in white blood cells
 monitoring must be done regularly
 Pharmacies must register to dispense
clozapine
 Specific day supply may be dispensed
 (1, 2, or 3 weeks depending on monitoring
frequency)
 Pharmacy must receive documentation of
blood work
Isotretinoin
 Treats severe acne & can cause serious birth
defects
 iPledge Program
 registration required by
 doctors
 patients
 Pharmacies
 must meet specific requirements / answer
questions with iPledge Program each time drug
dispensed
 quantity dispensed is limited
 prescription must be picked up within limited
Thalidomide
 Treats multiple myeloma/erythema nodosum
leprosum
 Causes birth defects
 Thalidomide Education & Prescribing
Safety (S.T.E.P.S.) Program
 prescribers, patients, pharmacies must register
 pharmacy must verify that the prescriber is
registered with S.T.E.P.S. before dispensing
medication
Dofetilide
 Treats irregular heart rhythms
 Can cause serious complications
 Patients must be hospitalized to initiate
therapy
 Tikosyn in Pharmacy System (T.I.P.S.)
 prescribers & pharmacists must register
 pharmacy must verify the prescriber’s
registration

More Related Content

What's hot

Drug Quality and Security Act
Drug Quality and Security ActDrug Quality and Security Act
Drug Quality and Security Act
Ben Comer
 

What's hot (18)

Combination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC DrugsCombination Products, Orphan Drugs and OTC Drugs
Combination Products, Orphan Drugs and OTC Drugs
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safety
 
Investigation of medicinal product dossier
Investigation of medicinal product dossierInvestigation of medicinal product dossier
Investigation of medicinal product dossier
 
Q1 2018 earnings charts final
Q1 2018 earnings charts   finalQ1 2018 earnings charts   final
Q1 2018 earnings charts final
 
FDA Regulation of Combination Products
FDA Regulation of Combination ProductsFDA Regulation of Combination Products
FDA Regulation of Combination Products
 
Reference Regulatory Authorities for Registration of Products in Drug Regula...
Reference Regulatory Authorities for Registration of Products in  Drug Regula...Reference Regulatory Authorities for Registration of Products in  Drug Regula...
Reference Regulatory Authorities for Registration of Products in Drug Regula...
 
Data exclusivity
Data exclusivityData exclusivity
Data exclusivity
 
Drug Quality and Security Act
Drug Quality and Security ActDrug Quality and Security Act
Drug Quality and Security Act
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
 
Controlled drugs
Controlled drugsControlled drugs
Controlled drugs
 
Galena presentation 22 sept 16
Galena presentation   22 sept 16Galena presentation   22 sept 16
Galena presentation 22 sept 16
 
Bellus corporate presentation march 23
Bellus corporate presentation march 23Bellus corporate presentation march 23
Bellus corporate presentation march 23
 
Galena presentation 13 sept 16
Galena presentation   13 sept 16Galena presentation   13 sept 16
Galena presentation 13 sept 16
 
21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)
 
Bellus health presentation september 14, 2017
Bellus health presentation   september 14, 2017Bellus health presentation   september 14, 2017
Bellus health presentation september 14, 2017
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 

Viewers also liked

REMS: the long tail can sting you
REMS: the long tail can sting youREMS: the long tail can sting you
REMS: the long tail can sting you
David Levin
 
Harvoni and Hepatitis C revised
Harvoni and Hepatitis C revisedHarvoni and Hepatitis C revised
Harvoni and Hepatitis C revised
Thomas Huang
 

Viewers also liked (13)

Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
 
Rems Presentation for FDA
Rems Presentation for FDARems Presentation for FDA
Rems Presentation for FDA
 
REMS: the long tail can sting you
REMS: the long tail can sting youREMS: the long tail can sting you
REMS: the long tail can sting you
 
N334 ACR Hammond
N334 ACR HammondN334 ACR Hammond
N334 ACR Hammond
 
Medical Cannabis and Inflammatory Bowel Disease
Medical Cannabis and Inflammatory Bowel DiseaseMedical Cannabis and Inflammatory Bowel Disease
Medical Cannabis and Inflammatory Bowel Disease
 
2015 Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...
2015   Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...2015   Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...
2015 Vivette Escueta enbrel pharmacoepidemiological study protocol - AAPS p...
 
Presentation
PresentationPresentation
Presentation
 
Psoriatic Arthritis and Connection to Diet: an Individualized Approach
Psoriatic Arthritis and Connection to Diet: an Individualized ApproachPsoriatic Arthritis and Connection to Diet: an Individualized Approach
Psoriatic Arthritis and Connection to Diet: an Individualized Approach
 
Zepatier (elbasvir and grazoprevir)
Zepatier (elbasvir and grazoprevir)Zepatier (elbasvir and grazoprevir)
Zepatier (elbasvir and grazoprevir)
 
Relapse.Remitting.MS
Relapse.Remitting.MSRelapse.Remitting.MS
Relapse.Remitting.MS
 
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...
 
Harvoni and Hepatitis C revised
Harvoni and Hepatitis C revisedHarvoni and Hepatitis C revised
Harvoni and Hepatitis C revised
 
BIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITISBIOLOGICS IN RHEUMATOID ARTHRITIS
BIOLOGICS IN RHEUMATOID ARTHRITIS
 

Similar to Restricteddrugpate

Gut_Bagatto_ Classic
Gut_Bagatto_ ClassicGut_Bagatto_ Classic
Gut_Bagatto_ Classic
Joseph Gut
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Until ROI
 

Similar to Restricteddrugpate (20)

MANAGEMENT OF MEDICATION IN HOSPITALS
MANAGEMENT OF MEDICATION IN HOSPITALSMANAGEMENT OF MEDICATION IN HOSPITALS
MANAGEMENT OF MEDICATION IN HOSPITALS
 
Hospital pharmacy
Hospital pharmacyHospital pharmacy
Hospital pharmacy
 
Cassualty assesment of adr
Cassualty assesment of adrCassualty assesment of adr
Cassualty assesment of adr
 
Gut_Bagatto_ Classic
Gut_Bagatto_ ClassicGut_Bagatto_ Classic
Gut_Bagatto_ Classic
 
importance of pharmcovigilance
importance of pharmcovigilanceimportance of pharmcovigilance
importance of pharmcovigilance
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, Cipla
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Adverse Drug Reactions - Katalyst HLS
Adverse Drug Reactions - Katalyst HLSAdverse Drug Reactions - Katalyst HLS
Adverse Drug Reactions - Katalyst HLS
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara VishaSynthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
Synthetic Drugs/Hormones - Boon or Bane- Concept of Dooshivisha and Gara Visha
 
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand PirouziHealth Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
 
Pharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koiralaPharmacovigilance by bishnu koirala
Pharmacovigilance by bishnu koirala
 
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringPHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
PHARMACOVIGILANCE - A Worldwide masterkey for Drug Monitoring
 
Towards Personalized Medicine
Towards Personalized MedicineTowards Personalized Medicine
Towards Personalized Medicine
 
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
 
Introduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxIntroduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptx
 
ZGNX Corporate Presentation OCT 2017
ZGNX Corporate Presentation OCT 2017ZGNX Corporate Presentation OCT 2017
ZGNX Corporate Presentation OCT 2017
 

More from cqpate (20)

STD
STDSTD
STD
 
Urinary noyouranary 2
Urinary noyouranary 2Urinary noyouranary 2
Urinary noyouranary 2
 
Corticosteroids
CorticosteroidsCorticosteroids
Corticosteroids
 
Antihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorantsAntihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorants
 
Firstaid
FirstaidFirstaid
Firstaid
 
Sterile enviroment
Sterile enviromentSterile enviroment
Sterile enviroment
 
Rx order
Rx orderRx order
Rx order
 
Retaildelivery
RetaildeliveryRetaildelivery
Retaildelivery
 
Regulatgion audit
Regulatgion auditRegulatgion audit
Regulatgion audit
 
Recordkeeping
RecordkeepingRecordkeeping
Recordkeeping
 
Recallsrefund
RecallsrefundRecallsrefund
Recallsrefund
 
Pointof saleinvenrtory
Pointof saleinvenrtoryPointof saleinvenrtory
Pointof saleinvenrtory
 
Effectofmeds
EffectofmedsEffectofmeds
Effectofmeds
 
Hospital drug rx
Hospital drug rxHospital drug rx
Hospital drug rx
 
Hospdelivery
HospdeliveryHospdelivery
Hospdelivery
 
Pharmadmin
PharmadminPharmadmin
Pharmadmin
 
Analgesics
AnalgesicsAnalgesics
Analgesics
 
Respiratorydrugs
RespiratorydrugsRespiratorydrugs
Respiratorydrugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 
Cardiovascularagentsnew
CardiovascularagentsnewCardiovascularagentsnew
Cardiovascularagentsnew
 

Recently uploaded

Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
EADTU
 

Recently uploaded (20)

How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
PANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxPANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
dusjagr & nano talk on open tools for agriculture research and learning
dusjagr & nano talk on open tools for agriculture research and learningdusjagr & nano talk on open tools for agriculture research and learning
dusjagr & nano talk on open tools for agriculture research and learning
 
Simple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdfSimple, Complex, and Compound Sentences Exercises.pdf
Simple, Complex, and Compound Sentences Exercises.pdf
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
VAMOS CUIDAR DO NOSSO PLANETA! .
VAMOS CUIDAR DO NOSSO PLANETA!                    .VAMOS CUIDAR DO NOSSO PLANETA!                    .
VAMOS CUIDAR DO NOSSO PLANETA! .
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
Model Attribute _rec_name in the Odoo 17
Model Attribute _rec_name in the Odoo 17Model Attribute _rec_name in the Odoo 17
Model Attribute _rec_name in the Odoo 17
 
Details on CBSE Compartment Exam.pptx1111
Details on CBSE Compartment Exam.pptx1111Details on CBSE Compartment Exam.pptx1111
Details on CBSE Compartment Exam.pptx1111
 
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
Transparency, Recognition and the role of eSealing - Ildiko Mazar and Koen No...
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Our Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdfOur Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdf
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 

Restricteddrugpate

  • 1. RESTRICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS With each drug/biologic safety issue posing a serious risk, the question for FDA will be: to REM or not to REM? REMS---Food and Drug Administration Amendments Act of 2007 in 2006 the FDA listed 156 REMS for prescription medicines (128) and biologics (28) intended to ensure the benefits of the medication outweigh its risk why REMS??--Public outcry over revelations of unforeseen risks from trusted medicines(rofecoxib, valdecoxib, and salmeterol
  • 2. RESTRICTED DRUGS  FDA can require a manufacturer to implement a REMS  Components of REMS  1--Medication Guides--required for drugs and biologics when the FDA determines that: (a) certain information is necessary to prevent serious adverse effects, (b) patient decision-making should be informed by information about a known serious side effect of a product, or (c) patient adherence to directions for the use of a product is essential to its effectiveness.
  • 3. RESTRICTED DRUGS  2--Communication Plans--  Letters to healthcare providers;  Disseminating information about the REMS to encourage implementation; and  Disseminating information through professional societies about any serious risks of the drug and any protocol to assure safe use.
  • 4. RESTRICTED DRUGS  3--Elements to Assure Safe Use(ETASU)  may include one or more of the following  Special training, certifications, or demonstration of experience for prescribers of the drug/biologic  Certification of pharmacies, practitioners, or healthcare settings that dispense the drug/biologic  Limitations as to the healthcare settings where the drug/biologic may be dispensed  Evidence of special safe-use conditions--patients receive the drug/biologic only after specified authorization,proof of counseling, periodic blood tests  monitor the number of prescriptions dispensed, adverse events,
  • 5. Examples of Drugs with REMS  alosetron (Lotronex)  clozapine (Clozaril, Fazaclo)  isotretinoin (Accutane, Amnesteem, Claravis, Sotret)  thalidomide (Thalomid)  dofetilide (Tikosyn)
  • 6. Alosetron  Treats a type of irritable bowel syndrome (IBS)  Serious adverse reactions of gastrointestinal tract  some necessitate a blood transfusion or surgery  some even lead to death  Restricted by Prescription Program for Lotronex (PPL)  requires physician enrollment & submission of Patient- Physician Agreement Form  Prescriptions must be written by physician & must include PPL sticker on face of prescription
  • 7. Clozapine  Treats patients with schizophrenia  Can cause serious drop in white blood cells  monitoring must be done regularly  Pharmacies must register to dispense clozapine  Specific day supply may be dispensed  (1, 2, or 3 weeks depending on monitoring frequency)  Pharmacy must receive documentation of blood work
  • 8. Isotretinoin  Treats severe acne & can cause serious birth defects  iPledge Program  registration required by  doctors  patients  Pharmacies  must meet specific requirements / answer questions with iPledge Program each time drug dispensed  quantity dispensed is limited  prescription must be picked up within limited
  • 9. Thalidomide  Treats multiple myeloma/erythema nodosum leprosum  Causes birth defects  Thalidomide Education & Prescribing Safety (S.T.E.P.S.) Program  prescribers, patients, pharmacies must register  pharmacy must verify that the prescriber is registered with S.T.E.P.S. before dispensing medication
  • 10. Dofetilide  Treats irregular heart rhythms  Can cause serious complications  Patients must be hospitalized to initiate therapy  Tikosyn in Pharmacy System (T.I.P.S.)  prescribers & pharmacists must register  pharmacy must verify the prescriber’s registration